藥明生物(02269.HK)升逾6% 分拆藥明合聯通過上市聆訊

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

藥明生物(02269.HK)升逾6% 分拆藥明合聯通過上市聆訊

阿思達克 10-30 09:47

藥明生物(02269.HK)分拆藥明合聯已通過上市聆訊，藥明系今日造好。藥明生物今日(30日)高開0.42%後升幅擴大，現報50.7元，升6.18%，成交621.52萬股，涉資3.07億元。藥明康德(02359.HK)今日低開0.66%後掉頭回升，現報103.6元，升5.5%，成交83.05萬股，涉資8,351.98萬元。藥明合聯截至6月底上半年收入按年大增2倍至9.9億元人民幣，利潤按年升80%至1.8億元人民幣。

药明生物(02269.HK)

药明康德(02359.HK)